Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Algernon Pharmaceuticals Inc.
C.AGN
Alternate Symbol(s):
AGNPF
Consumer Cyclical
Healthcare
Advertising Agencies
Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N...
-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Company Website
Add To Watchlist
Bullboard (CSE:AGN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(1359)
•••
Pandora
X
View Profile
View Bullboard History
Comment by
Pandora
on Feb 28, 2023 11:02pm
RE:100/1 Reverse Split Now Calculated As 25/1 Reverse Split.
And your $1.68 share now goes back to 42 cents. Quite the ride.
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on Feb 28, 2023 10:57pm
100/1 Reverse Split Now Calculated As 25/1 Reverse Split.
YOU'VE BEEN MENTALLY TWISTED LIKE A PRETZEL (Nasdaq Uplist...LOL)
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Feb 28, 2023 8:45pm
New Press Release - Algernon Pharmaceuticals Announces 4 for 1 Forward Share Split
VANCOUVER, British Columbia, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company announces that effective at the opening of markets on March 3, 2023, the Class...
read article.
(38)
•••
StockHawk1
X
View Profile
View Bullboard History
Post by
StockHawk1
on Feb 28, 2023 4:43pm
AGO CEO on the DMT-TBI study
Algernon Pharmaceuticals' (AGN.c AGNPF) CEO recently went to Radius Research to discuss the company's new clinical research program. AGN plans to investigate if DMT can treat Traumatic
...more
(16)
•••
waves1
X
View Profile
View Bullboard History
Comment by
waves1
on Feb 27, 2023 5:24pm
RE:News Brief: $AGN CEO Chris Moreau Begins TBI Research AP-188
It's great to see AGN expanding its portfolio, especially given this program can be accelerated directly to Phase 2 in Q4 2023 with the data from its Phase 1 DMT study for stroke
(16)
•••
waves1
X
View Profile
View Bullboard History
Comment by
waves1
on Feb 24, 2023 4:25pm
RE:AGN to use Stroke research to accelerate TBI study
AGN is positioning itself at the forefront of DMT research as they now have two studies investigating its use - as the industry around psychedelics continues to develop, AGN could face some solid
...more
(38)
•••
StockHawk1
X
View Profile
View Bullboard History
Post by
StockHawk1
on Feb 23, 2023 3:52pm
AGN to use Stroke research to accelerate TBI study
Algernon Pharmaceuticals' (AGN.c AGNPF) subsidiary, AGN Neuro, has added a new clinical research program to investigate treating Traumatic Brain Injury with DMT. AGN hopes to use data
...more
(37)
•••
bmreed
X
View Profile
View Bullboard History
Post by
bmreed
on Feb 23, 2023 3:18pm
News Brief: $AGN CEO Chris Moreau Begins TBI Research AP-188
News Brief: Algernon Pharmaceuticals $AGN w CEO Christopher Moreau - Initiates Traumatic Brain Injury (TBI) Research Program with AP-188 - https://youtu.be/sN5fFFvCPHc Algernon
...more
(16)
•••
waves1
X
View Profile
View Bullboard History
Post by
waves1
on Feb 22, 2023 2:04pm
Radius Research CEO interview on TBI research program
AGN CEO on Radius Research regarding the TBI research program
...more
(268)
•••
stockpatrol
X
View Profile
View Bullboard History
Post by
stockpatrol
on Feb 21, 2023 6:00pm
$GMG.v received approval for its graphene products from the
$GMG.v received approval for its graphene products from the Australian Industrial Chemicals Introduction Scheme (AICIS), bringing an increase the production and sale of its graphene-enhanced products
...more
(16)
•••
waves1
X
View Profile
View Bullboard History
Post by
waves1
on Feb 21, 2023 2:11pm
AGN expands psychedelic portfolio w/ DMT for TBI study
AGN continuing to expand its psychedelic portfolio with the addition of a new clinical research program for the treatment of TBI with DMT! Using the data from its Phase 1 Study of DMT for Stroke
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Feb 21, 2023 7:00am
New Press Release - Algernon NeuroScience Initiates Traumatic Brain Injury Research Program With DMT; Appoints Global TBI Expert as Advisor
VANCOUVER, British Columbia, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro...
read article.
(16)
•••
waves1
X
View Profile
View Bullboard History
Post by
waves1
on Feb 17, 2023 2:22pm
AGN CEO on the latest DMT study update
AGN CEO on Proactive discussing the latest update on its Phase
...more
(37)
•••
bmreed
X
View Profile
View Bullboard History
Post by
bmreed
on Feb 17, 2023 12:11pm
Phase 1 DMT Trial Update with $AGN CEO Christopher Moreau
News Update: Algernon Pharmaceuticals $AGN w CEO Christopher Moreau - Phase 1 DMT Trial Update - https://youtu.be/6xROQOlIfaY {^youtubevideo|(width)425|(height)264|(rel)False|(url)https://youtu.be
...more
(38)
•••
StockHawk1
X
View Profile
View Bullboard History
Post by
StockHawk1
on Feb 16, 2023 4:44pm
AGN.c DMT-stroke study update
Algernon Pharmaceuticals (AGN.c AGNPF) closed in the green today after sharing updates on its Phase 1 DMT Clinical Study AGN has finished dosing the first set of patients. The safety review
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Mining Player Sells Off Promising Project for Millions – Here's Where the Cash is Headed
EnviroGold Global Announces Appointment of Chief Operating Officer